Tags

Type your tag names separated by a space and hit enter

Effectiveness of allergic rhinitis treatments in real-life with a focus on MP-AzeFlu.
Expert Rev Clin Pharmacol. 2016; 9(5):705-14.ER

Abstract

For any allergic rhinitis (AR) treatment, it is crucial to provide evidence not only of efficacy (assessed in randomized controlled trials (RCTs)) but also of effectiveness in real-life. Observational studies provide valuable data on the use and results associated with interventions prescribed in real-life. However, real-life evidence supporting available AR treatment options is sparse with effectiveness only established for oral antihistamines (desloratadine, ebastine), intranasal corticosteroids (mometasone furoate, fluticasone propionate (FP)), allergen immunotherapy and omalizumab. A novel intranasal formulation of azelastine hydrochloride and FP in a single spray (MP-AzeFlu) shows great promise, with the effectiveness observed in real-life exceeding that noted in RCTs. This review summarises real-life data on MP-AzeFlu, which provides rapid and sustained symptom control irrespective of patient age, AR phenotype or disease severity. We call for high quality real-life research in addition to RCTs to inform future AR treatment guidelines.

Authors+Show Affiliations

a Center for Rhinology and Allergology , Wiesbaden , Germany.b Département de Pneumologie et Addictologie , University Hospital of Montpellier , Montpellier , France.c Division of Applied Health Sciences , University of Aberdeen , Aberdeen , UK.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

26839083

Citation

Klimek, Ludger, et al. "Effectiveness of Allergic Rhinitis Treatments in Real-life With a Focus On MP-AzeFlu." Expert Review of Clinical Pharmacology, vol. 9, no. 5, 2016, pp. 705-14.
Klimek L, Demoly P, Price D. Effectiveness of allergic rhinitis treatments in real-life with a focus on MP-AzeFlu. Expert Rev Clin Pharmacol. 2016;9(5):705-14.
Klimek, L., Demoly, P., & Price, D. (2016). Effectiveness of allergic rhinitis treatments in real-life with a focus on MP-AzeFlu. Expert Review of Clinical Pharmacology, 9(5), 705-14. https://doi.org/10.1586/17512433.2016.1148598
Klimek L, Demoly P, Price D. Effectiveness of Allergic Rhinitis Treatments in Real-life With a Focus On MP-AzeFlu. Expert Rev Clin Pharmacol. 2016;9(5):705-14. PubMed PMID: 26839083.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effectiveness of allergic rhinitis treatments in real-life with a focus on MP-AzeFlu. AU - Klimek,Ludger, AU - Demoly,Pascal, AU - Price,David, Y1 - 2016/02/27/ PY - 2016/2/4/entrez PY - 2016/2/4/pubmed PY - 2016/12/21/medline KW - Allergic rhinitis KW - MP-AzeFlu KW - effectiveness KW - real-life SP - 705 EP - 14 JF - Expert review of clinical pharmacology JO - Expert Rev Clin Pharmacol VL - 9 IS - 5 N2 - For any allergic rhinitis (AR) treatment, it is crucial to provide evidence not only of efficacy (assessed in randomized controlled trials (RCTs)) but also of effectiveness in real-life. Observational studies provide valuable data on the use and results associated with interventions prescribed in real-life. However, real-life evidence supporting available AR treatment options is sparse with effectiveness only established for oral antihistamines (desloratadine, ebastine), intranasal corticosteroids (mometasone furoate, fluticasone propionate (FP)), allergen immunotherapy and omalizumab. A novel intranasal formulation of azelastine hydrochloride and FP in a single spray (MP-AzeFlu) shows great promise, with the effectiveness observed in real-life exceeding that noted in RCTs. This review summarises real-life data on MP-AzeFlu, which provides rapid and sustained symptom control irrespective of patient age, AR phenotype or disease severity. We call for high quality real-life research in addition to RCTs to inform future AR treatment guidelines. SN - 1751-2441 UR - https://www.unboundmedicine.com/medline/citation/26839083/Effectiveness_of_allergic_rhinitis_treatments_in_real_life_with_a_focus_on_MP_AzeFlu_ L2 - https://www.tandfonline.com/doi/full/10.1586/17512433.2016.1148598 DB - PRIME DP - Unbound Medicine ER -